SRRK Earnings

SRRK reported its FY2025Q3 earnings on 2025-11-14, showcasing a revenue of 0.00 against an estimate of 50.00K, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.88 by 0% . The stock experienced a 24.41% price change on the earnings day and a 31.99% change over the next five days, reflecting market reactions to the results.

Following SRRK's FY2025Q3 earnings announcement on 2025-11-14, the stock price moved by 24.41% on the day of the release. Over the subsequent five days, it saw a 31.99% change. Historically, SRRK's stock price tends to shift by an average of +1.84% in the 10 days leading up to earnings and -1.06% in the 10 days following, providing insight into potential market.

For , analysts estimate SRRK’s annual revenue to reach , while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -85.55% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SRRK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -85.55%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SRRK's stock price typically moves by +1.84% in the 10 days before its earnings and -1.06% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -1.00 and revenue of .

The earnings call summary indicates solid financial performance, strategic global expansion, and strong cash runway into 2027. The Q&A session reveals proactive risk management and strategic financing, with a focus on minimizing operational disruptions and ensuring FDA compliance. Although some uncertainties exist regarding the reinspection timeline, the company's strategic investments and optimistic guidance suggest a positive outlook. The stock price is likely to increase by 2% to 8% over the next two weeks, driven by the company's strategic initiatives and financial health.